Lonza, a global manufacturing partner for the pharmaceutical, biotech, and nutraceutical industries, has announced capacity expansions at its Rewari (India) and Suzhou (China) facilities. The additions include new manufacturing lines for hard gelatin capsules (HGCs), designed to support the production
Merck, a science and technology company, has entered into a definitive agreement to acquire HUB Organoids Holding B.V., a Netherlands-based pioneer in organoid technology. The acquisition aims to enhance Merck’s expertise in next-generation biology and drug discovery. Terms of the
Merck, operating as MSD outside the US and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, have entered into a global licensing agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the terms of the agreement,
Catalent, Inc., a leader in drug development and manufacturing solutions, is now part of Novo Holdings following a completed acquisition valued at approximately $16.5 billion. The all-cash transaction grants holders of Catalent common stock $63.50 per share, representing a 47.5%
BioCentriq, a CDMO specialising in cell therapy, has entered into a long-term lease for a new state-of-the-art facility in Princeton, New Jersey. This facility, spanning 60,000 square feet, will serve as the company’s headquarters and strengthen its position in the
RTI Surgical, a CDMO in tissue engineering and regenerative medicine, has announced its rebranding as Evergen. This marks the company’s evolution into a top-tier Contract Development and Manufacturing Organization (CDMO) focused on innovative biosolutions. The rebranding follows a pivotal year,
Upperton, a contract development and manufacturing organisation (CDMO), has appointed Lorna Patrick as Chief Operating Officer to support its growth strategy. Lorna will lead operational teams across research, development, manufacturing, analytics, and project management functions. With over 20 years of
Rocketvax AG, a Swiss biotech leader, has teamed up with HALIX B.V., a top-tier Contract Development and Manufacturing Organization (CDMO), to bolster global pandemic readiness. The partnership will leverage Rocketvax’s innovative VIRUFLEX platform, designed to accelerate vaccine development in response
Samsung Biologics, a contract development and manufacturing services provider (CDMO), has been recognised for the fourth consecutive year in the prestigious Dow Jones Sustainability World Index (DJSI). This accolade highlights the company’s ongoing commitment to integrating sustainable business practices throughout
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has announced the establishment of a U.S.-based subsidiary, Scinai Bioservices Inc., incorporated in Delaware. The new unit will focus on providing contract development and manufacturing (CDMO) services to early-stage biotech companies, addressing a critical gap
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
